Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. The company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.
The company’s in-house discovery engine is using unique live-cell imaging technologies, patient-derived cell lines and predictive cell-based disease models to build a portfolio of promising compounds.
Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of mitochondrial diseases.
To accelerate the discovery and development of its potential medicines for mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally.
Khondrion is headquartered in Nijmegen, The Netherlands.
Prof. Dr. Jan Smeitink
Prof. Dr. Jan Smeitink is CEO and founder of Khondrion.
With more than 25 years’ experience in patient care, diagnostics and research for patients suffering from mitochondrial disease, Jan is the Founder and CEO of Khondrion. He also holds a position as Professor in Mitochondrial Medicine at the Radboud University Medical Center (RUMC) in the Netherlands and has been appointed foreign adjunct professor at the Karolinska Institutet in Stockholm, Sweden. In addition, he coordinates the Radboud Center for Mitochondrial Medicine (RCMM) at the Radboud UMC. He has published more than 375 peer-reviewed scientific papers.
Dr. Julien Beyrath
Dr. Julien Beyrath is Chief Operating Officer and Scientific Officer at Khondrion.
Julien holds a PhD in molecular and cellular biology with a major in Pharmacology from the University of Strasbourg, France. Prior to working at Khondrion, Julien was a researcher at the Centre for Systems Biology and Bioenergetics of the Radboud University Medical Center, the Netherlands, focusing on the identification of new drug targets for mitochondrial disease. He has expertise in the discovery of drug candidates and their pre-clinical development. Julien is responsible for internal and external research and development programs and manages the day-to-day operations of the Khondrion laboratories.
Dr. Svetlana Pecheritsyna
Svetlana Pecheritsyna is a researcher at Khondrion.
Svetlana is a researcher with extensive knowledge of cell biology. Within SysMedPD, she is responsible for planning and execution of experiments aimed at identifying disease related phenotype in cell-based assays and novel drug candidates to ameliorate mitochondrial defects in patient-derived cells.
Iris Pelgrim is a Junior Researcher at Khondrion.
Iris holds a MSc in Molecular Nutrition & Toxicology. She contributes to the SysmedPD project by focusing on phenotypic characterisation of fibroblast and NESC cultures in 2D, and the development of in vitro assays required to accomplish this.